The rough endoplasmic reticulum synthesizes proteins while the function of the smooth endoplasmic reticula is to synthesize steroids and lipids; regulate calcium concentration, drug metabolism, as well as attachment of receptors on cell membrane proteins; and metabolize steroids (but not lipids) and carbohydrates.
Developing New Polymer-Based Medicines for Undertreated Conditions. Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. We are focused on developing medicines that will change treatment paradigms.
A REMS (Risk Evaluation and Mitigation Strategy) is a program required by the Food and Drug Administration to manage known or potential serious risks associated with a drug product. The ProliaÂ® REMS program materials are designed to inform healthcare providers and patients about these risks with ProliaÂ®. They include a REMS Letter for Healthcare Providers, Patient Counseling Chart for Healthcare Providers, Patient Brochure, Journal Information Piece, Prescribing Information, and Medication Guide.